Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation-Reference-Cited by-同舟云学术

Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation

Published:2020-10 Issue:10 Volume:26 Page:1876-1885
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Chhabra Saurabh,Visotcky Alexis,Pasquini Marcelo C.,Zhu Fenlu,Tang Xiaoying,Zhang Mei-Jie,Thompson Robert,Abedin Sameem,D'Souza Anita,Dhakal Binod,Drobyski William R.,Fenske Timothy S.,Jerkins James H.,Douglas Rizzo J.,Runaas Lyndsey,Saber Wael,Shah Nirav N.,Shaw Bronwen E.,Horowitz Mary M.,Hari Parameswaran N.,Hamadani Mehdi

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference63 articles.

1. Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review;Koreth;Biol Blood Marrow Transplant,2009

2. Treatment of chronic graft-versus-host disease with bortezomib;Pai;Blood,2014

3. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research;Arai;Biol Blood Marrow Transplant,2015

4. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation;Antin;Blood,2003

5. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors;Nash;Blood,2000

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers;JAMA Oncology;2024-08-29

2. Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma;International Journal of Hematology;2023-04-15

3. Ixazomib for Desensitization (IXADES) in Highly Sensitized Kidney Transplant Candidates: A Phase II Clinical Trial;Kidney360;2023-03-23

4. A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial;Transplantation and Cellular Therapy;2022-07

5. GVHD Pathogenesis, Prevention and Treatment: Lessons From Humanized Mouse Transplant Models;Frontiers in Immunology;2021-07-29